Anchora Medical is a technology company.
Anchora Medical has raised $5.0M across 1 funding round.
Anchora Medical has raised $5.0M in total across 1 funding round.
Anchora Medical has raised $5.0M in total across 1 funding round.
Anchora Medical's investors include Alon MedTech Ventures.
Anchora Medical is an Israel-based medical device company founded in 2014 that develops the Su2ura Approximation Device, a sterile, single-use suturing tool for approximating soft tissue in open and minimally invasive surgeries (MIS), such as hernia repairs[1][2][3][5]. The device uses tiny stainless steel anchors threaded on surgical thread to enable continuous or interrupted sutures via a single-trigger operation, simplifying suturing in endoscopic and open procedures[1][2][3]. It targets surgeons and healthcare providers facing challenges with traditional suturing in MIS, addressing inefficiencies in tissue approximation; the company raised $4.5M in 2020 led by HOYA Corporation, signaling early growth momentum amid demand for advanced surgical tools[3].
Anchora Medical emerged from the vision of serial entrepreneurs in Israel's medtech ecosystem, founded in 2014 to revolutionize suturing 150 years after sewing machines became commonplace, extending those principles to MIS[1]. Key founders include a prominent serial entrepreneur and investor who co-founded Syneron-Candela (acquired for $397M by APAX), Lumenis (acquired for $510M by XIO), and invested in Ventor (acquired by Medtronic for $325M); Yoni, with 15+ years in medtech including co-founding InnoLap Surgical (acquired by Teleflex); a Technion MD/PhD with 10+ years co-founding firms like Polytouch (acquired by Covidien); and an engineering veteran with 20 years prototyping for companies like Lumenis and InnoLap[1]. Early traction included a $4.5M financing round in 2020, validating their anchor-based continuous suturing innovation[3].
Anchora rides the wave of MIS expansion, where global demand for faster, less invasive procedures grows amid aging populations and rising surgical volumes; suturing remains a bottleneck in ~10-15% of MIS cases, making automated tools timely[1][3]. Favorable market forces include medtech M&A activity (evident in founders' exits) and investor interest, as seen in their HOYA-led funding during a period of surgical innovation post-2020[3]. Anchora influences the ecosystem by advancing anchor-based suturing, potentially standardizing easier MIS techniques and inspiring similar single-use devices in Israel's thriving medtech hub (Caesarea/Yokneam base)[1][3].
Anchora's trajectory points to regulatory milestones (e.g., FDA/CE approval) and partnerships with surgical giants like Teleflex or Medtronic, leveraging team exits for scale-up and commercialization[1][3]. Trends like robotic-assisted surgery and AI-enhanced tools will amplify demand for simplified suturing, positioning Anchora to capture share in the $5B+ soft tissue repair market. Its influence may evolve from innovator to acquirer target, fueling Israel's medtech momentum—echoing its founding promise to make advanced suturing as intuitive as a sewing machine[1].
Anchora Medical has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series B in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $5.0M Series B | Alon MedTech Ventures |